The NK-92 cell line is employed in most of the other phase I/II studies, targeting CD7 (NCT02742727) for lymphoma and leukemia, CD33 for the treatment of Acute Myeloid Leukemia (NCT02944162), HER2 against glioblastoma (NCT03383978) and Mucin-1 (MUC1) in MUC1-positive relapsed or refractory solid tumor-like colorectal carcinoma (CRC) and gastric carcinoma. This evidence concerns the gene MUC1 and leukemia.